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Abstract
Spinal cord injury (SCI) has a huge impact on the individual, society and the economy. Though 
advances in acute care resulted in greatly reduced co-morbidities, there has been much less 
progress preventing long-term sequelae of SCI. Among the long-term consequences of SCI is 
bone loss (osteoporosis) due to the mechanical unloading of the paralyzed limbs and vascular 
dysfunction below the level of injury. Though osteoporosis may be partially prevented via 
pharmacologic interventions during the acute post-injury phase, there are no clinical guidelines to 
treat osteoporosis during the chronic phase. Thus there is need for scientific advances to improve 
the rehabilitative approaches to SCI-related osteoporosis. Recent advances in application of a new 
technology, functional electrical stimulation, provide a new and exciting opportunity to improve 
bone metabolism and to provide mechanical strain to the paralyzed lower limbs sufficient to 
stimulate new bone formation in individuals with SCI. The purpose of this minireview is to 
delineate our current understanding of SCI-related osteoporosis and to highlight recent literature 
towards its prevention and treatment.
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There are approximately six million people living with spinal cord injury (SCI)-related 
paralysis in the United States – nearly one in every 50 people. Though advances in acute 
care resulted in greatly reduced co-morbidities in the initial few years following a spinal 
cord injury, there has been much less progress preventing medical complications associated 
with SCI in the long-term. Therefore, understanding the long-term consequences of SCI is 
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tcritical to develop evidence-based rehabilitation programs that would provide optimal 
treatment for the reversal of co-morbidities.
Individuals with SCI are at increased risk for developing an array of inactivity-related health 
problems during the chronic stages of injury. Among several consequences of SCI is bone 
loss (osteoporosis) following injury, which is both rapid in onset and severe in nature. In 
motor complete SCI, the long bones of the lower extremity adapt to minimal mechanical 
strain by atrophying. Bone loss occurs rapidly in the acute phase of the injury and slows two 
to three years after injury [1]. While the nature and magnitude of the effects of SCI on bone 
vary by skeletal site, sex, and age [2], all individuals with motor complete SCI develop 
osteoporosis below the level of the injury [1,3,4]. Perhaps as a result, individuals with 
complete SCI are twice as likely to experience fractures compared to healthy controls [5], 
and as many as 40% of the individuals with chronic SCI experience fractures [5–8], with the 
most common occurrence at the metaphyses of the proximal tibia and distal femur [9]. 
Fractures are discovered after minimal trauma and are most commonly treated with 
prolonged bed-rest and bracing in many cases. However, the combination of the injury and 
extended bracing results in prolonged immobility, worsening disability, and serious medical 
complications, such as pressure ulcer formation, increased pain and spasticity, and lower 
extremity amputation. Thus, it is critical to develop rehabilitation programs that may 
effectively reverse the sequelae of prolonged lower extremity disuse and minimize the 
medical complications due to osteoporosis secondary to lower extremity paralysis. 
Unfortunately, however, physical therapy does not appear to have proven efficacy [10], and 
there are no studies that conclusively showed an effective pharmacologic intervention for 
prevention and treatment of osteoporosis in chronic SCI [11]. Part of the culprit may be that 
only a small number of individuals with SCI volunteer for long-term studies, and adequately 
matching individuals by the level, completes, and duration of lesion, as well as age is not 
always possible [7,11]. Thus long-term longitudinal randomized investigations on 
osteoporosis in individuals with SCI have been difficult. Nevertheless, the lack of effective 
rehabilitative strategies underlines the importance of an integrated understanding of the 
factors, both neural and local, that are involved. The purpose of this mini-review is to 
delineate our current understanding of SCI-related osteoporosis and to highlight recent 
literature towards its prevention and treatment.
Neural Denervation, Limb Unloading, and Mechanisms of Bone Loss 
Following SCI
Trabecular and cortical bone as well as the bone marrow are innervated by sympathetic 
neural fibers [12–15], and functional noradrenaline and various neuropeptide receptors have 
been identified on bone cells [16,17]. Thus, sympathetic innervation appears to play an 
important role in bone function. In fact, experimental sympathetic denervation in animal 
models results in reduced bone deposition and mineralization and increased bone resorption 
[18,19], suggesting a potential direct impact of denervation on bone function. In addition to 
its direct impact, sympathetic denervation may also have an indirect impact on bone 
metabolism via vascular dysregulation. For example, interruption of sympathetic signaling 
causes the opening of bone intravenous shunts, leading to venous and capillary vascular 
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tstasis [20,21]. Among the consequences of vascular stasis is osteoclast formation due to 
local hyper-pressure, which may accelerate bone resorption [22]. Therefore, vascular 
dysfunction below the level of injury may promote and/or facilitate the development of 
osteoporosis.
In addition to nervous denervation and subsequent vascular alterations, the rapid loss of 
bone due to any type of prolonged immobilization is also related to limb unloading and 
consequent alterations in calciotropic hormones and local messenger systems [23]. The 
general consensus is that SCI-related bone loss occurs in 2 phases: 1) a rapid, acute phase 
characterized by increased bone resorption that plateaus somewhere between 18–24 months 
post-injury and 2) a chronic phase, characterized by inhibition of bone formation with 
ongoing bone loss that is more gradual in nature [24–27]. Early studies of circulating levels 
of bone turnover markers in SCI subjects reported that bone formation is suppressed 
immediately following SCI [28]. Other reports using animal models of hind limb unloading 
have described immediate osteocyte and osteoblast apoptosis [29], and an increased 
osteoclastic bone resorption with reduced bone formation [30]. Thus, mechanical unloading 
following SCI leads to a rapid increase in bone resorption by osteoclasts and suppresses 
bone formation by osteoblasts, ultimately leading to bone loss.
The discovery of the role of Wnt signaling pathways in bone homeostasis has radically 
transformed our understanding of the cellular and molecular mechanisms responsible for the 
adaptation of bone to unloading [31,32]. While Wnt signaling pathways include a large 
family of growth factors that participate in various developmental events, these pathways are 
also implicated in adult homeostatic mechanisms [24,33]. For example, dysfunction of Wnt 
pathways have been implicated in a variety of degenerative diseases and abnormalities, 
including those associated with impaired bone homeostasis [34]. Indeed, several studies in 
rodents have defined the central role of Wnt signaling antagonists in the pathogenesis of 
disuse osteoporosis. Osteocytes, the cells responsible for mechano-transduction in bone, 
represent the first cellular response to unloading [35], and release sclerostin, a potent Wnt 
signaling antagonist [36–38]. Several studies have shown that sclerostin levels are inversely 
proportional to bone mass and that production of sclerostin by osteocytes is dramatically 
reduced by mechanical loading [1,37,39]. Thus, mechanical unloading results in up-
regulation of sclerostin, which leads to reduced Wnt/β-catenin signaling in osteoblasts and to 
inhibition of bone formation and growth. Moreover, sclerostin causes up-regulation of 
RANKL (a key factor that promotes osteoclast differentiation), and down-regulation of 
osteoprotegerin (a key inhibitor of osteoclast differentiation) expression by osteocytes, 
which leads to increased osteoclast activity and ultimately to bone resorption [40,41]. Thus, 
in addition to its anti-anabolic role, sclerostin also appears to have catabolic effects.
Recent work has also shown a positive relation between circulating sclerostin levels and 
bone density in chronic (>5 years) immobility in humans. Considering the mechanism of 
sclerostin-induced bone loss in acute SCI, this relation in the chronic phase seems 
paradoxical at first. However, though sclerostin levels may initially increase after SCI in 
response to mechanical unloading, in the long-term, circulating sclerostin may serve as a 
biomarker of osteoporosis severity and not a mediator of ongoing bone loss. Indeed, recent 
research supports this duality. On one hand, sclerostin levels are greatest in subjects with 
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tshort-term SCI and decrease significantly over the first 5 years post-injury [42]. On the other 
hand, in subjects with long-term (>5 years post-injury) SCI, sclerostin levels are positively 
associated with lower extremity bone density and bone mineral content [42].
Pharmacologic Strategies Toward Treatment of Osteoporosis Following 
SCI
Currently there are no clinical guidelines for the prevention or reversal of SCI-related 
osteoporosis. Traditionally, bisphosphonates have been considered as the most appropriate 
therapy to prevent bone loss following SCI. Bisphosphonates strongly inhibit bone 
resorption. Various reports indicate that they provide an effective preventive treatment 
strategy when initiated within 12 months of the injury [43–46], and early bisphosphonate 
administration increase ash weight, maximal torque capacity, maximal angle capacity and 
rigidity of the bone atrophied by immobilization [47]. However, the efficacy of 
bisphosphonate treatment appears to be limited to only within the acute phase (< 1 year) of 
injury [48]. This may be related to the fact that though bisphosphonates reduce bone 
resorption, they have limited effect on bone formation [49]. This is explained by the fact that 
bisphosphonates reduce coupled bone remodeling because they suppress osteoclastic bone 
resorption, which is required in order for osteoblastic bone formation to proceed.
The role of sclerostin in the adaptation of bone to unloading during the acute phase of SCI 
suggests that sclerostin may provide an alternative therapeutic target during the acute phase 
of injury as a prevention strategy to prevent initial, rapid osteoporosis. The higher sclerostin 
levels in acute SCI and lower levels in chronic SCI strongly suggest that the time frame for 
limiting bone resorption is limited. Thus, there may be an optimal time frame - the 
“therapeutic window” - for targeting sclerostin and preventing bone loss following SCI [6]. 
Unfortunately, however, there is no longitudinal information that defines the kinetics of 
bone loss and its relation to circulating sclerostin in the acute phase of SCI (i.e., within the 
first year), when acute mechanical unloading and most bone loss occurs.
The ongoing discussion suggests that although bone loss in individuals with SCI may be 
partially prevented via pharmacologic interventions, notably during the acute post-injury 
phase, current pharmacologic treatments do not appear to be capable of reversing bone 
demineralization. Thus, currently there is no effective pharmacologic intervention for 
prevention and treatment of disuse osteoporosis due to SCI, especially after the first year of 
injury. Perhaps as a consequence, a recent, emerging theme in the literature is the utility of 
novel, non-pharmacologic paradigms that are specifically designed for individuals with SCI 
to prevent and reverse the bone loss due to prolonged immobility.
Physical Exercise and Effective Reversal of Osteoporosis Following SCI
Bone is a dynamic organ that modulates the rate of new bone formation in response to 
varying levels of physical exercise and mechanical strain, and there is already ample 
evidence that physical exercise in those with SCI is broadly beneficial to health [50,51], 
improves quality of life [52], and impacts outcome after SCI [53]. Therefore, it would not 
come as a surprise that physical exercise can reduce, prevent, and even reverse SCI-related 
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tosteoporosis. There is evidence of improved circulation in bone vasculature during muscular 
work. For example, recent work has shown that resting femoral bone blood flow almost 
doubles in response to isometric exercise, although the increase in blood flow plateaus with 
increasing exercise intensities [54]. The blood flow response to muscular work appears to be 
mediated by a metabolically induced stimulus, rather than neural mechanisms [55]. Thus, 
physical exercise may promote bone blood flow, alleviate the bone vascular dysfunction due 
to neural denervation, and facilitate bone metabolism and growth in SCI. Furthermore, 
mechanical loading of the bone during exercise may reverse the alterations in local Wnt 
signaling cascade that occur due to immobilization and unloading, contributing to disuse 
osteoporosis. Therefore, it is conceivable that re-introduction of mechanical loading via 
physical exercise may also reverse atrophy and bone loss in individuals with SCI.
However, though a majority of SCI patients regard physical activity as important, more than 
half do not have access to appropriate exercise [56]. For the general population, physical 
exercise is an inexpensive, safe, and effective approach for avoiding health problems. 
However, a typical individual with SCI experiences many barriers to exercise due to their 
immobility, such as the inability to use a large portion of their muscle mass, and inability to 
locate appropriate facilities and affordable equipment. Fortunately, exercise programs based 
on functional electrical stimulation (FES) have been developed to overcome these barriers. 
FES-exercise uses electrical stimulation of the paralyzed muscles to cause muscle 
contractions. Loading the bones through muscular contractions initiated by FES has yielded 
positive results. For example, in both acute and chronic SCI, up-right standing via force 
feedback-controlled electrical stimulation of paralyzed quadriceps appears to provide 
sufficient loading to the paralyzed lower limbs closer to load levels with known osteogenic 
potential [57]. Moreover, recent adaptation of cycling and rowing exercises for FES 
provides a new and exciting opportunity to provide mechanical strain to the paralyzed lower 
limbs sufficient to stimulate bone formation in individuals with SCI.
Recent research has shown that FES-cycling initiated during the very early stages of spinal 
cord injury (1 – 2 months post-injury) may attenuate the bone loss [58], though at least one 
study show that this may not be the case [59]. However, the attenuation of bone loss fades 
quickly, within 6 months once cycling exercise is discontinued [58,60]. Though the reasons 
for these discrepant results are unknown, one culprit may be the limited mechanical 
efficiency of cycling exercise. In all individuals, able-bodied or not, exercise must meet 
certain intensity and volume criteria to induce significant health benefits. For example, 
passive weight bearing of paralyzed lower extremities appears to be ineffective, and the 
intensity, frequency, and duration of stress to the bones appear to be important determinants 
of improved bone parameters [9]. Yet, the mechanical efficiency of FES-cycling is 
estimated as ~8% [61], less than a third of that for cycling in ablebodied individuals. One 
issue may be that cycling exercise does not achieve high levels of aerobic work and a 
plateau in training effect is quickly reached [62]. Therefore, though promising, this modality 
of FES-exercise may not be sufficient to promote enough bone blood flow and mechanical 
strain to reliably prevent and reverse SCI-mediated bone loss beyond the very early stages of 
injury.
Tan et al. Page 5
Int J Phys Med Rehabil. Author manuscript; available in PMC 2014 November 20.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tIn contrast to typical FES cycling exercise, it appears that significant benefits can be 
achieved via high volume FES cycling training. For example, in patients with chronic SCI, 
high-volume (five 60-min training sessions a week for 12 months) FES cycling training can 
partially reverse the loss of bone mineral density [63]. Moreover, though the benefits 
achieved through 1 year of high volume FES cycling training may be lost if the training 
discontinues, the benefits appear to be maintained when reduced intensity exercise is 
continued after the initial training [64]. Recently, in an attempt to overcome the limitations 
of typical FES-cycling, rowing has been adapted for FES exercise to provide a better 
exercise modality for individuals with SCI. FES-rowing uses electrical stimulation of the 
paralyzed quadriceps and hamstrings to actively engage both the arms and the legs in the full 
rowing cycle. Though it is currently unknown if FES-rowing can prevent osteoporosis 
during acute phase of SCI, a recent pilot study from our laboratory with three individuals 
with chronic SCI has shown that the cyclical mechanical loading of the lower extremities 
during FES-rowing can promote new bone formation (up to 50%), improve bone strength, 
and may revert osteoporosis during the chronic stage of SCI [65]. Further studies are 
required to assess the utility of FES-rowing on effective reversal of SCI-mediated 
osteoporosis. Nevertheless, FES-rowing appears to provide sufficient exercise intensity and 
mechanical strain to the paralyzed lower limbs to stimulate new bone formation. In addition 
to the improvement in musculoskeletal health, the advantages of FES-rowing exercise 
include an improvement in cardiovascular health more than most options currently available 
[66], the use of a relatively inexpensive ergometer, and integration into existing rowing 
programs and communities because of its similarity to rowing by the general population. 
According to participants, FES-rowing is intuitive and easy to learn, and a more engaging 
and natural exercise, similar to what would be used by able-bodied individuals. Moreover, 
FES exercise has been shown to be safe for participants [67], and FES-rowing paradigm has 
been used in our laboratory for exercise by more than 100 individuals with SCI over the past 
5 years without any adverse events. Therefore, FES-rowing is offers many new and exciting 
physiological, economic, and social opportunities for the SCI population.
Conclusions and Future Directions for Rehabilitative Strategies
Chronic SCI and consequent osteoporosis have a huge impact on the individual, society and 
the economy, and thus there is need for scientific advances to improve the effectiveness of 
rehabilitative approaches. In rehabilitation medicine, the shortage of evidence-based practice 
has been a major barrier to advancing care and promoting the timely identification, 
application, and assessment of advances in science and technology with the potential to 
improve rehabilitation outcomes in chronic SCI. For example, sclerostin may provide an 
alternative therapeutic target during the acute phase of injury as a prevention strategy to 
prevent initial, rapid osteoporosis, and to improve rehabilitation outcomes in chronic stages. 
However, future work should define the kinetics of bone loss and its relation to circulating 
sclerostin when acute mechanical unloading and most bone loss occur. In addition, recent 
advances in application of a new technology (functional electrical stimulation) provide an 
exciting new avenue to improve functional mobility, to foster behavioral adaptation to 
functional losses, and to further facilitate development of improved assistive technologies 
for individuals with chronic SCI. Future work should address both the physiologic and 
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tclinical impact of FES exercise and develop exercise programs that can provide loading to 
the paralyzed lower limbs sufficient not only to prevent osteoporosis but also to promote 
osteogenesis to ensure effective reversal of SCI-mediated osteoporosis.
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